| pubmed-article:12567057 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C0025202 | lld:lifeskim |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C0029016 | lld:lifeskim |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C0085862 | lld:lifeskim |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C1299583 | lld:lifeskim |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C1514475 | lld:lifeskim |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C1608386 | lld:lifeskim |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C1549571 | lld:lifeskim |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:12567057 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:12567057 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:12567057 | pubmed:dateCreated | 2003-2-4 | lld:pubmed |
| pubmed-article:12567057 | pubmed:abstractText | For 25 years, the Breslow depth of primary tumors has remained the most accurate prognostic test of survival for primary melanoma. However a number of studies have indicated that outcome for intermediate-thickness melanomas (0.75-2.49 mm) is often at variance with that predicted by the Breslow depth. This study investigated c-myc oncogene expression in 92 primary tumors of intermediate thickness using flow cytometry. Oncoprotein expression was detected in 87 tumors (95%) with a median positivity of 48% (range, 0%-96%). Survival analysis performed using the Kaplan-Meier method revealed a significant association between oncoprotein positivity and clinical outcome (p < 0.01, log-rank test). Multifactorial analysis of survival using Cox's proportional hazards model revealed c-myc oncoprotein to be an independent prognostic marker more accurate than all other clinicopathological parameters including the Breslow depth (chi(2) = 9.68, p< 0.01). Estimation of c-myc oncoprotein is therefore recommended as a powerful prognostic marker for intermediate-thickness primary melanoma. | lld:pubmed |
| pubmed-article:12567057 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12567057 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12567057 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12567057 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12567057 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12567057 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:12567057 | pubmed:issn | 0148-7043 | lld:pubmed |
| pubmed-article:12567057 | pubmed:author | pubmed-author:SandersRoyR | lld:pubmed |
| pubmed-article:12567057 | pubmed:author | pubmed-author:GroverRajivR | lld:pubmed |
| pubmed-article:12567057 | pubmed:author | pubmed-author:WilsonGeorge... | lld:pubmed |
| pubmed-article:12567057 | pubmed:author | pubmed-author:PacificoMarc... | lld:pubmed |
| pubmed-article:12567057 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12567057 | pubmed:volume | 50 | lld:pubmed |
| pubmed-article:12567057 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12567057 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12567057 | pubmed:pagination | 183-7 | lld:pubmed |
| pubmed-article:12567057 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:meshHeading | pubmed-meshheading:12567057... | lld:pubmed |
| pubmed-article:12567057 | pubmed:year | 2003 | lld:pubmed |
| pubmed-article:12567057 | pubmed:articleTitle | Use of oncogene expression as an independent prognostic marker for primary melanoma. | lld:pubmed |
| pubmed-article:12567057 | pubmed:affiliation | RAFT Institute of Plastic Surgery, Mount Vernon Hospital, Northwood, Middlesex HA6 2RN, UK. | lld:pubmed |
| pubmed-article:12567057 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12567057 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
